Prediction of pCR with pretreatment MRI radiomics in triple negative breast cancer treated with neoadjuvant chemo-immunotherapy.
Toulsie Ramtohul,Victoire Lepagnay,Claire Bonneau,Maxime Jin,Emmanuelle Menet,Juliette Sauge,Enora Laas,Emanuela Romano,Diana Bello,Fatima Mechta-Grigoriou,Francois Clement Bidard,Adriana Langer,Caroline Malhaire,Luc Cabel,Anne Tardivon
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.589
IF: 45.3
2024-05-31
Journal of Clinical Oncology
Abstract:589 Background: Neoadjuvant chemo-immunotherapy (NACI) has become the new standard of care for stage II-III triple-negative breast cancers (TNBC). This approach is linked to high rates of pathological complete responses (pCR), yet factors influencing responses to this regimen remain poorly characterized. Our objective was to investigate whether pretreatment MRI perfusion-based radiomics could serve as a predictive tool for pCR to NACI in patients with TNBC. Methods: This prospective study enrolled women with early-stage TNBC undergoing NACI at two different centers from August 2021 to July 2023. Tumor segmentation and pharmacokinetic analyses of pretreatment multi-vendor dynamic-contrast-enhanced (DCE)-MRI were conducted using the standard perfusion Tofts model. Radiomics features were extracted from the K trans , V e , and Slope max maps. Unsupervised correlation analysis of reproducible features and least absolute shrinkage and selector operation were employed to construct a radiomics score. The performance of the radiomic score was evaluated using the area under the receiver operating characteristic curve (AUC). A multivariable logistic regression model was employed to establish a multimodal nomogram. Performance metrics included discrimination, calibration, and clinical usefulness, assessed on the external validation set. Results: The training set comprised 112 patients from center 1 (mean age, 52 years ± 11 [SD]), and the external validation set included 83 participants from center 2 (mean age, 49 years ± 11 [SD]). Overall, the pCR rate was 70% (137/195). In the validation set, the radiomic score achieved an AUC of 0.80 (95% CI: 0.70, 0.89) for predicting pCR. A nomogram incorporating the radiomics score, tumor grade, and Ki67 yielded an AUC of 0.86 (95% CI: 0.78, 0.94) and demonstrated superior predictive efficacy compared to the histological prediction model (AUC, 0.76 [95% CI: 0.66, 0.87]; P = .02) in the validation set. Calibration curves of the nomogram exhibited good concordance between predicted and observed pCR in both sets. The radiomic score correlated with tumor size, washout enhancement curve, androgen receptor (AR), and combined positive score (CPS) PD-L1 levels (all P < 0.05). Conclusions: PretreatmentMRI-based radiomics is a reliable predictor of pCR to NACI and might help customizing treatment choice for early-stage TNBC patients.
oncology